131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma

Inclusion Criteria: * Histologically confirmed marginal zone B-cell lymphoma * relapsed or refractory patients after treatment including chemotherapy, radiation therapy, and surgery * Eastern Cooperative Oncology Group performance status ≤ 2 * age≥ 20 years * More than one measurable lesion (More than 2cm sized lesion in conventional CT scan, More than 1cm sized lesion in spiral CT or contrast-enhanced PET/CT ) * Adequate renal function (serum creatinine ≤ 2.0 mg/dl or Ccr ≥ 60 ml/min) * Adequate hepatic function (serum bilirubin ≤ 2.0 mg/dl , AST/ALT ≤ 3 upper normal limit) * Adequate bone marrow reservoir (ANC ≥1,500/㎕, platelet count≥ 75,000/㎕) * patient who agree the purpose and intention of this clinical trial Exclusion Criteria: * recent (\<5 years) history of other malignancy or unrecovered from the disease (appropriately treated skin cancer and uterine cervix carcinoma in situ are excluded) * hemodynamically unstable due to the recent (\<12 months) history of severe heart disease such as myocardial infarction * acute complications of severe lung or metabolic disease * Combined severe neurological or psychiatric disease * Unrecovered from infection or other medical disease * Recent (\<30 days) history of enrollment of other clinical trial * Pregnant or breast-feeding woman * women of childbearing potential and men not employing adequate contraception at least for 1 year * Previous history drug allergy to the content of 131I-rituximab * Infection(sepsis, pneumonia, viral infection, etc) (inactivated hepatitis B carrier can be enrolled)